Carregant...
Acquired Resistance to Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice (Tamoxifen & Raloxifene) by Selection Pressure in Breast Cancer Cell Populations
Tamoxifen, a pioneering selective estrogen receptor modulator (SERM), has long been a therapeutic choice for all stages of estrogen receptor (ER)-positive breast cancer. The clinical application of long-term adjuvant antihormone therapy for the breast cancer has significantly improved breast cancer...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4192097/ https://ncbi.nlm.nih.gov/pubmed/24930824 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.steroids.2014.06.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|